John R. Pinion II

2019

In 2019, John R. Pinion II earned a total compensation of $3.4M as Chief Quality Officer and Executive Vice President, Translational Sciences at Ultragenyx Pharmaceutical, a 111% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$205,490
Option Awards$923,578
Salary$447,690
Stock Awards$1,756,300
Other$37,472
Total$3,370,530

Pinion received $1.8M in stock awards, accounting for 52% of the total pay in 2019.

Pinion also received $205.5K in non-equity incentive plan, $923.6K in option awards, $447.7K in salary and $37.5K in other compensation.

Rankings

In 2019, John R. Pinion II's compensation ranked 3,632nd out of 13,971 executives tracked by ExecPay. In other words, Pinion earned more than 74.0% of executives.

ClassificationRankingPercentile
All
3,632
out of 13,971
74th
Division
Manufacturing
1,312
out of 5,701
77th
Major group
Chemicals And Allied Products
456
out of 2,200
79th
Industry group
Drugs
382
out of 1,886
80th
Industry
Pharmaceutical Preparations
287
out of 1,398
80th
Source: SEC filing on April 29, 2020.

Pinion's colleagues

We found four more compensation records of executives who worked with John R. Pinion II at Ultragenyx Pharmaceutical in 2019.

2019

Emil Kakkis

Ultragenyx Pharmaceutical

Chief Executive Officer

2019

Shalini Sharp

Ultragenyx Pharmaceutical

Chief Financial Officer

2019

Camille Bedrosian

Ultragenyx Pharmaceutical

Chief Medical Officer

2019

Thomas Kassberg

Ultragenyx Pharmaceutical

Chief Business Officer and Executive Vice President

News

You may also like